Chemotherapy plus targeted therapies shows improved survival in advance-stage lung cancer patients

The combination of traditional chemotherapy agents with targeted therapies called monoclonal antibodies showed no safety concerns and improved survival in patients with advanced non-small cell lung cancer according to a study presented at the 2008 Chicago Multidisciplinary Symposium in Thoracic Oncology.

If you want to include this story in your blog, copy and paste this formatted text:

<p><a href="http://www.physorg.com/news145800276.html">Chemotherapy plus targeted therapies shows improved survival in advance-stage lung cancer patients</a></p> <p>The combination of traditional chemotherapy agents with targeted therapies called monoclonal antibodies showed no safety concerns and improved survival in patients with advanced non-small cell lung cancer according to a study presented at the 2008 Chicago Multidisciplinary Symposium in Thoracic Oncology. </p>